Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention.

@article{Kao2004RelationOM,
  title={Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention.},
  author={John Kao and J. M. Tobis and Robyn L. McClelland and Melissa R Heaton and Barry R. Davis and David R. Holmes and Jesse W. Currier},
  journal={The American journal of cardiology},
  year={2004},
  volume={93 11},
  pages={1347-50, A5}
}
Diabetic patients undergoing coronary interventions have worse clinical and angiographic outcomes than do patients without diabetes. Metformin, an insulin sensitizer, may decrease the occurrence of these outcomes. Diabetic patients in the Prevention of Restenosis with Tranilast and its Outcomes Trial were identified through their medical records (n = 2,772). In this trial, 1,110 diabetic patients received nonsensitizer therapy (insulin and/or sulfonylureas) and 887 received sensitizer therapy… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Cardiovascular safety of anti-diabetic drugs.

European heart journal. Cardiovascular pharmacotherapy • 2016
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 16 references

PPAR-gamma effects on the vasculature.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research • 2001

Effect of intensive blood - glucose ontrol with metformin on complications in overweight patients with type 2 iabetes ( UKPDS 34 )

RW Stout
Lancet • 1998

Similar Papers

Loading similar papers…